Verona Pharma begins RPL554 dosing in Phase IIb trial for COPD

UK-based biopharmaceutical firm Verona Pharma has begun dosing patients in a Phase IIb clinical trial of RPL554 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news